Have questions about diabetes management?
Hear what the experts are saying about the latest therapies, side effects, and cost considerations.

Subscribe to CME Podcast Download iTunes - Free


Session 1:
Thiazolidinediones (TZDs)

Apply for CME credit

What are the relative merits/disadvantages of pioglitazone and rosiglitazone, two TZD drugs?

At what ejection fraction value would you not use pioglitazone for fear of exacerbating congestive heart failure?



Session 2:
Incretins

Apply for CME credit

What are the pros and cons of injectable incretins and orally available DPP-4 inhibitors?

My patients tend to gain weight with insulin and SU drugs. Is this side effect observed with DPP-4 inhibitors and incretins?



Session 3:
Side Effects

Apply for CME credit

Exenatide frequently causes nausea in my patients; what strategies can help manage this side effect?



Session 4:
Exenatide Safety & Emerging Agents

Apply for CME credit

Pancreatitis has been reported in patients treated with exenatide. Is this AE drug-related, and is it observed with sitagliptin?

There are other DPP-4 inhibitors in clinical development. What are the distinguishing features of the emerging drugs?


 


Session 5:
Combinations of Drugs

Apply for CME credit

The ADA consensus panel preferred metformin as the front line agent. What is the best strategy for adding insulin, TZDs, incretins, DPP-4 inhibitors or SUs to metformin?

What are the special considerations for obesity, renal impairment, liver disease, or other comorbidities?



Session 6:
Cost Considerations

Apply for CME credit


Cost of medications is a key factor for chronic diseases such as diabetes. Isn't the combination of metformin + pioglitazone + incretin mimetic/DDP-4 much more expensive than using metformin and insulin?

Are the clinical advantages of incretins and DPP-4 inhibitors worth the price difference?


PC   MAC  
right click to download   Click to play or right click on link to download file.   Click to play or control click on link to download file.